Glucagon Like Peptide-1 Agonists Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Drug ( EXENATIDE, Liraglutide, Dulaglutide, Lixisenatide ) and Geography
Report Code: TIPRE00008997 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
GLP-1 receptor agonist medicines, also called incretin mimetics, are a type of incretin-based medicine for type 2 diabetes. This type of medicine is based on the action of hormones called incretins, which help control how the pancreas works. The drugs, also commonly known as glucagon-like peptide 1 (GLP-1) receptor agonists or GLP-1 analogues, are normally prescribed for patients who have not been able to control their condition with tablet medication.
MARKET DYNAMICS
Increasing diabetes prevalence in established and emerging countries, along with the increase of geriatric population is expected to drive the market. However, side effects associated with the glucagon like peptide-1 agonists may impede the market growth.
MARKET SCOPE
`
The "Global Glucagon Like Peptide-1 Agonists Market analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Glucagon Like Peptide-1 Agonists Market with detailed market segmentation by, drug and geography. The Global Glucagon Like Peptide-1 Agonists Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Glucagon Like Peptide-1 Agonists Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Global Glucagon Like Peptide-1 Agonists Market is segmented on the basis of drug. On the basis of drug, the Global Glucagon Like Peptide-1 Agonists Market is categorized into exenatide, liraglutide, dulaglutide, lixisenatide.
?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Glucagon Like Peptide-1 Agonists Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Glucagon Like Peptide-1 Agonists Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Glucagon Like Peptide-1 Agonists Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Glucagon Like Peptide-1 Agonists Market in these regions.
The report covers key developments in the Glucagon Like Peptide-1 Agonists Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Glucagon Like Peptide-1 Agonists Market are anticipated to lucrative growth opportunities in the future with the rising demand for Glucagon Like Peptide-1 Agonists Market in the global market. Below mentioned is the list of few companies engaged in the Glucagon Like Peptide-1 Agonists Market.
The report also includes the profiles of key Glucagon Like Peptide-1 Agonists Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- NovoNordisk
- Sanofi
- Eli Lilly
- AstraZeneca
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization `options in the existing study.
GLP-1 receptor agonist medicines, also called incretin mimetics, are a type of incretin-based medicine for type 2 diabetes. This type of medicine is based on the action of hormones called incretins, which help control how the pancreas works. The drugs, also commonly known as glucagon-like peptide 1 (GLP-1) receptor agonists or GLP-1 analogues, are normally prescribed for patients who have not been able to control their condition with tablet medication.
MARKET DYNAMICS
Increasing diabetes prevalence in established and emerging countries, along with the increase of geriatric population is expected to drive the market. However, side effects associated with the glucagon like peptide-1 agonists may impede the market growth.
MARKET SCOPE
`
The "Global Glucagon Like Peptide-1 Agonists Market analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Glucagon Like Peptide-1 Agonists Market with detailed market segmentation by, drug and geography. The Global Glucagon Like Peptide-1 Agonists Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Glucagon Like Peptide-1 Agonists Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Global Glucagon Like Peptide-1 Agonists Market is segmented on the basis of drug. On the basis of drug, the Global Glucagon Like Peptide-1 Agonists Market is categorized into exenatide, liraglutide, dulaglutide, lixisenatide.
?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Glucagon Like Peptide-1 Agonists Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Glucagon Like Peptide-1 Agonists Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Glucagon Like Peptide-1 Agonists Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Glucagon Like Peptide-1 Agonists Market in these regions.
The report covers key developments in the Glucagon Like Peptide-1 Agonists Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Glucagon Like Peptide-1 Agonists Market are anticipated to lucrative growth opportunities in the future with the rising demand for Glucagon Like Peptide-1 Agonists Market in the global market. Below mentioned is the list of few companies engaged in the Glucagon Like Peptide-1 Agonists Market.
The report also includes the profiles of key Glucagon Like Peptide-1 Agonists Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- NovoNordisk
- Sanofi
- Eli Lilly
- AstraZeneca
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization `options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Glucagon Like Peptide-1 Agonists Market - By Drug
1.3.2 Glucagon Like Peptide-1 Agonists Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET - GLOBAL MARKET ANALYSIS
6.1. GLUCAGON LIKE PEPTIDE-1 AGONISTS - GLOBAL MARKET OVERVIEW
6.2. GLUCAGON LIKE PEPTIDE-1 AGONISTS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG
7.1. OVERVIEW
7.2. DRUG MARKET FORECASTS AND ANALYSIS
7.3. EXENATIDE
7.3.1. Overview
7.3.2. EXENATIDE Market Forecast and Analysis
7.4. LIRAGLUTIDE
7.4.1. Overview
7.4.2. Liraglutide Market Forecast and Analysis
7.5. DULAGLUTIDE
7.5.1. Overview
7.5.2. Dulaglutide Market Forecast and Analysis
7.6. LIXISENATIDE
7.6.1. Overview
7.6.2. Lixisenatide Market Forecast and Analysis
8. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Glucagon Like Peptide-1 Agonists Market Overview
8.1.2 North America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.1.3 North America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.1.4 North America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.1.4.1 United States Glucagon Like Peptide-1 Agonists Market
8.1.4.1.1 United States Glucagon Like Peptide-1 Agonists Market by Drug
8.1.4.2 Canada Glucagon Like Peptide-1 Agonists Market
8.1.4.2.1 Canada Glucagon Like Peptide-1 Agonists Market by Drug
8.1.4.3 Mexico Glucagon Like Peptide-1 Agonists Market
8.1.4.3.1 Mexico Glucagon Like Peptide-1 Agonists Market by Drug
8.2. EUROPE
8.2.1 Europe Glucagon Like Peptide-1 Agonists Market Overview
8.2.2 Europe Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.2.3 Europe Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.2.4 Europe Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Glucagon Like Peptide-1 Agonists Market
8.2.4.1.1 Germany Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.2 France Glucagon Like Peptide-1 Agonists Market
8.2.4.2.1 France Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.3 Italy Glucagon Like Peptide-1 Agonists Market
8.2.4.3.1 Italy Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.4 Spain Glucagon Like Peptide-1 Agonists Market
8.2.4.4.1 Spain Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.5 United Kingdom Glucagon Like Peptide-1 Agonists Market
8.2.4.5.1 United Kingdom Glucagon Like Peptide-1 Agonists Market by Drug
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Overview
8.3.2 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.3.3 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.3.4 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Glucagon Like Peptide-1 Agonists Market
8.3.4.1.1 Australia Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.2 China Glucagon Like Peptide-1 Agonists Market
8.3.4.2.1 China Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.3 India Glucagon Like Peptide-1 Agonists Market
8.3.4.3.1 India Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.4 Japan Glucagon Like Peptide-1 Agonists Market
8.3.4.4.1 Japan Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.5 South Korea Glucagon Like Peptide-1 Agonists Market
8.3.4.5.1 South Korea Glucagon Like Peptide-1 Agonists Market by Drug
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Overview
8.4.2 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.4.3 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.4.4 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Glucagon Like Peptide-1 Agonists Market
8.4.4.1.1 South Africa Glucagon Like Peptide-1 Agonists Market by Drug
8.4.4.2 Saudi Arabia Glucagon Like Peptide-1 Agonists Market
8.4.4.2.1 Saudi Arabia Glucagon Like Peptide-1 Agonists Market by Drug
8.4.4.3 U.A.E Glucagon Like Peptide-1 Agonists Market
8.4.4.3.1 U.A.E Glucagon Like Peptide-1 Agonists Market by Drug
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Glucagon Like Peptide-1 Agonists Market Overview
8.5.2 South and Central America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.5.3 South and Central America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.5.4 South and Central America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Glucagon Like Peptide-1 Agonists Market
8.5.4.1.1 Brazil Glucagon Like Peptide-1 Agonists Market by Drug
8.5.4.2 Argentina Glucagon Like Peptide-1 Agonists Market
8.5.4.2.1 Argentina Glucagon Like Peptide-1 Agonists Market by Drug
9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
10. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET, KEY COMPANY PROFILES
10.1. NOVONORDISK
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. SANOFI
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. ELI LILLY
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. ASTRAZENECA
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Glucagon Like Peptide-1 Agonists Market - By Drug
1.3.2 Glucagon Like Peptide-1 Agonists Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET - GLOBAL MARKET ANALYSIS
6.1. GLUCAGON LIKE PEPTIDE-1 AGONISTS - GLOBAL MARKET OVERVIEW
6.2. GLUCAGON LIKE PEPTIDE-1 AGONISTS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG
7.1. OVERVIEW
7.2. DRUG MARKET FORECASTS AND ANALYSIS
7.3. EXENATIDE
7.3.1. Overview
7.3.2. EXENATIDE Market Forecast and Analysis
7.4. LIRAGLUTIDE
7.4.1. Overview
7.4.2. Liraglutide Market Forecast and Analysis
7.5. DULAGLUTIDE
7.5.1. Overview
7.5.2. Dulaglutide Market Forecast and Analysis
7.6. LIXISENATIDE
7.6.1. Overview
7.6.2. Lixisenatide Market Forecast and Analysis
8. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Glucagon Like Peptide-1 Agonists Market Overview
8.1.2 North America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.1.3 North America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.1.4 North America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.1.4.1 United States Glucagon Like Peptide-1 Agonists Market
8.1.4.1.1 United States Glucagon Like Peptide-1 Agonists Market by Drug
8.1.4.2 Canada Glucagon Like Peptide-1 Agonists Market
8.1.4.2.1 Canada Glucagon Like Peptide-1 Agonists Market by Drug
8.1.4.3 Mexico Glucagon Like Peptide-1 Agonists Market
8.1.4.3.1 Mexico Glucagon Like Peptide-1 Agonists Market by Drug
8.2. EUROPE
8.2.1 Europe Glucagon Like Peptide-1 Agonists Market Overview
8.2.2 Europe Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.2.3 Europe Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.2.4 Europe Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Glucagon Like Peptide-1 Agonists Market
8.2.4.1.1 Germany Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.2 France Glucagon Like Peptide-1 Agonists Market
8.2.4.2.1 France Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.3 Italy Glucagon Like Peptide-1 Agonists Market
8.2.4.3.1 Italy Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.4 Spain Glucagon Like Peptide-1 Agonists Market
8.2.4.4.1 Spain Glucagon Like Peptide-1 Agonists Market by Drug
8.2.4.5 United Kingdom Glucagon Like Peptide-1 Agonists Market
8.2.4.5.1 United Kingdom Glucagon Like Peptide-1 Agonists Market by Drug
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Overview
8.3.2 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.3.3 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.3.4 Asia-Pacific Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Glucagon Like Peptide-1 Agonists Market
8.3.4.1.1 Australia Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.2 China Glucagon Like Peptide-1 Agonists Market
8.3.4.2.1 China Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.3 India Glucagon Like Peptide-1 Agonists Market
8.3.4.3.1 India Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.4 Japan Glucagon Like Peptide-1 Agonists Market
8.3.4.4.1 Japan Glucagon Like Peptide-1 Agonists Market by Drug
8.3.4.5 South Korea Glucagon Like Peptide-1 Agonists Market
8.3.4.5.1 South Korea Glucagon Like Peptide-1 Agonists Market by Drug
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Overview
8.4.2 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.4.3 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.4.4 Middle East and Africa Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Glucagon Like Peptide-1 Agonists Market
8.4.4.1.1 South Africa Glucagon Like Peptide-1 Agonists Market by Drug
8.4.4.2 Saudi Arabia Glucagon Like Peptide-1 Agonists Market
8.4.4.2.1 Saudi Arabia Glucagon Like Peptide-1 Agonists Market by Drug
8.4.4.3 U.A.E Glucagon Like Peptide-1 Agonists Market
8.4.4.3.1 U.A.E Glucagon Like Peptide-1 Agonists Market by Drug
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Glucagon Like Peptide-1 Agonists Market Overview
8.5.2 South and Central America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis
8.5.3 South and Central America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Drug
8.5.4 South and Central America Glucagon Like Peptide-1 Agonists Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Glucagon Like Peptide-1 Agonists Market
8.5.4.1.1 Brazil Glucagon Like Peptide-1 Agonists Market by Drug
8.5.4.2 Argentina Glucagon Like Peptide-1 Agonists Market
8.5.4.2.1 Argentina Glucagon Like Peptide-1 Agonists Market by Drug
9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
10. GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET, KEY COMPANY PROFILES
10.1. NOVONORDISK
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. SANOFI
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. ELI LILLY
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. ASTRAZENECA
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
The List of Companies
1. NovoNordisk
2. Sanofi
3. Eli Lilly
4. AstraZeneca
1. NovoNordisk
2. Sanofi
3. Eli Lilly
4. AstraZeneca